NAV

Romifidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Romifidine
DrugBank Accession Number
DB11543
Background

Romifidine is a veterinary drug utilized as a sedative primarily in large animals, most frequently horses. It is also used less commonly in a wide variety of other animal species. This drug's chemical structure closely resembles that of clonidine, however, romifidine is not approved for use in humans.

Type
Small Molecule
Groups
Vet approved
Structure
3D
Similar Structures
Weight
Average: 258.094
Monoisotopic: 256.996388
Chemical Formula
C9H9BrFN3
Synonyms
  • Romifidine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Romifidine is combined with 1,2-Benzodiazepine.
AcebutololThe therapeutic efficacy of Romifidine can be decreased when used in combination with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Romifidine.
AcemetacinThe risk or severity of hypertension can be increased when Romifidine is combined with Acemetacin.
AcetazolamideThe risk or severity of CNS depression can be increased when Acetazolamide is combined with Romifidine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Romifidine hydrochloride98LQ6RS0TA65896-14-2SDXVSIWCVTYYQN-UHFFFAOYSA-N
International/Other Brands
Sedivet

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Aniline and substituted anilines
Direct Parent
Aniline and substituted anilines
Alternative Parents
Fluorobenzenes / Bromobenzenes / Aryl fluorides / Aryl bromides / Imidazolines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
2-imidazoline / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Aryl bromide / Aryl fluoride / Aryl halide / Azacycle / Bromobenzene / Carboximidamide / Fluorobenzene
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
876351L05K
CAS number
65896-16-4
InChI Key
KDPNLRQZHDJRFU-UHFFFAOYSA-N
InChI
InChI=1S/C9H9BrFN3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
IUPAC Name
N-(2-bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine
SMILES
FC1=CC=CC(Br)=C1NC1=NCCN1

References

General References
  1. England GC, Watts N: Effect of romifidine and romifidine-butorphanol for sedation in dogs. J Small Anim Pract. 1997 Dec;38(12):561-4. [Article]
  2. England GC, Flack TE, Hollingworth E, Hammond R: Sedative effects of romifidine in the dog. J Small Anim Pract. 1996 Jan;37(1):19-25. [Article]
  3. Browning AP, Collins JA: Sedation of horses with romifidine and butorphanol. Vet Rec. 1994 Jan 22;134(4):90-1. [Article]
  4. Pypendop BH, Verstegen JP: Cardiovascular effects of romifidine in dogs. Am J Vet Res. 2001 Apr;62(4):490-5. [Article]
  5. Selmi AL, Barbudo-Selmi GR, Moreira CF, Martins CS, Lins BT, Mendes GM, McManus C: Evaluation of sedative and cardiorespiratory effects of romifidine and romifidine-butorphanol in cats. J Am Vet Med Assoc. 2002 Aug 15;221(4):506-10. [Article]
  6. Aithal HP, Amarpal, Kinjavdekar P, Pawde AM, Pratap K: Analgesic and cardiopulmonary effects of intrathecally administered romifidine or romifidine and ketamine in goats (Capra hircus). J S Afr Vet Assoc. 2001 Jun;72(2):84-91. [Article]
  7. Freeman SL, Bowen IM, Bettschart-Wolfensberger R, Alibhai HI, England GC: Cardiovascular effects of romifidine in the standing horse. Res Vet Sci. 2002 Apr;72(2):123-9. [Article]
  8. Marzok M, El-Khodery S: Sedative and analgesic effects of romifidine in camels (Camelus dromedarius). Vet Anaesth Analg. 2009 Jul;36(4):352-60. doi: 10.1111/j.1467-2995.2009.00473.x. [Article]
  9. Selmi AL, Figueiredo JP, Mendes GM, Lins BT: Effects of tiletamine/zolazepam-romifidine-atropine in ocelots (Leopardus pardalis). Vet Anaesth Analg. 2004 Jul;31(3):222-6. [Article]
  10. Gomez-Villamandos RJ, Redondo JI, Martin EM, Dominguez JM, Granados MM, Estepa JC, Ruiz I, Aguilera E, Santisteban JM: Romifidine or medetomidine premedication before propofol-sevoflurane anaesthesia in dogs. J Vet Pharmacol Ther. 2005 Oct;28(5):489-93. [Article]
KEGG Drug
D08487
ChemSpider
64975
RxNav
1091919
ChEMBL
CHEMBL2105424
ZINC
ZINC000056898821
Wikipedia
Romifidine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0859 mg/mLALOGPS
logP2.21ALOGPS
logP2.19Chemaxon
logS-3.5ALOGPS
pKa (Strongest Basic)8.06Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area36.42 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity57.32 m3·mol-1Chemaxon
Polarizability21.06 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-00p0-9810000000-843b957f694532270f98
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-c526a484dcb56f7e6b0d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-30f7888e42797408a08b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-bf096fdf22f665a14ca6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-059i-4980000000-f80fe8a84b8f92a5a8f1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052o-8920000000-92181caab292f8cbecd5
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03fu-9070000000-bbed4d7d525611d4f925
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-135.89308
predicted
DeepCCS 1.0 (2019)
[M+H]+138.69878
predicted
DeepCCS 1.0 (2019)
[M+Na]+147.45358
predicted
DeepCCS 1.0 (2019)

Drug created at February 26, 2016 17:41 / Updated at February 21, 2021 18:53